EPS for BioTime, Inc. (BTX) Expected At $-0.06; Algert Global Upped By $362,608 Its Intest (INTT) Stake

February 15, 2018 - By Ruchi Gupta

Analysts expect BioTime, Inc. (NYSEAMERICAN:BTX) to report $-0.06 EPS on March, 15.After having $-0.05 EPS previously, BioTime, Inc.’s analysts see 20.00% EPS growth. The stock increased 1.92% or $0.05 during the last trading session, reaching $2.65. About 386,038 shares traded. BioTime, Inc. (NYSEAMERICAN:BTX) has risen 22.71% since February 15, 2017 and is uptrending. It has outperformed by 6.01% the S&P500.

Algert Global Llc increased Intest Corp (INTT) stake by 32.79% reported in 2017Q3 SEC filing. Algert Global Llc acquired 45,326 shares as Intest Corp (INTT)’s stock rose 60.00%. The Algert Global Llc holds 183,563 shares with $1.52M value, up from 138,237 last quarter. Intest Corp now has $82.38M valuation. The stock increased 1.91% or $0.15 during the last trading session, reaching $8. About 27,413 shares traded. inTEST Corporation (NYSEMKT:INTT) has risen 107.79% since February 15, 2017 and is uptrending. It has outperformed by 91.09% the S&P500.

Algert Global Llc decreased Landstar Sys Inc (NASDAQ:LSTR) stake by 19,309 shares to 7,475 valued at $745,000 in 2017Q3. It also reduced Emcor Group Inc (NYSE:EME) stake by 5,483 shares and now owns 16,986 shares. Liberty Tax Inc (NASDAQ:TAX) was reduced too.

Investors sentiment decreased to 1.69 in 2017 Q3. Its down 3.71, from 5.4 in 2017Q2. It turned negative, as 7 investors sold INTT shares while 6 reduced holdings. 8 funds opened positions while 14 raised stakes. 4.89 million shares or 45.13% less from 8.91 million shares in 2017Q2 were reported. Morgan Stanley holds 0% or 12,961 shares. Northern Corp holds 26,038 shares or 0% of its portfolio. 67,122 were accumulated by Eam Invsts Limited Liability Corporation. The Massachusetts-based Acadian Asset Ltd Limited Liability Company has invested 0% in inTEST Corporation (NYSEAMERICAN:INTT). 44,100 were reported by Spark Invest Limited Liability Company. 31,576 were accumulated by California Public Employees Retirement. Royal State Bank Of Canada, Ontario – Canada-based fund reported 13,328 shares. Seizert Capital Prtnrs Limited Liability Corp has 0.03% invested in inTEST Corporation (NYSEAMERICAN:INTT). Hillsdale Invest reported 0.14% stake. Bard Associate Incorporated has 1.31% invested in inTEST Corporation (NYSEAMERICAN:INTT) for 338,790 shares. Prelude Capital Ltd Liability Corporation holds 0% or 3,543 shares. Blackrock reported 0% in inTEST Corporation (NYSEAMERICAN:INTT). Lsv Asset reported 0% in inTEST Corporation (NYSEAMERICAN:INTT). 642 are owned by Bankshares Of America De. Nokomis Cap Ltd Liability invested in 2.58% or 1.16M shares.

Since September 27, 2017, it had 0 buys, and 5 selling transactions for $2.39 million activity. Another trade for 938 shares valued at $8,161 was made by MATTHIESSEN ROBERT E on Friday, October 27. Nokomis Capital – L.L.C. sold 120,000 shares worth $1.13 million. SATTERFIELD THOMAS A JR had sold 93,769 shares worth $777,816.

Since October 13, 2017, it had 1 buying transaction, and 0 selling transactions for $7.00 million activity. The insider BROADWOOD PARTNERS – L.P. bought 2.69 million shares worth $7.00 million.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $336.20 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It has a 6.16 P/E ratio. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

Investors sentiment decreased to 1.96 in 2017 Q3. Its down 0.17, from 2.13 in 2017Q2. It dived, as 9 investors sold BioTime, Inc. shares while 15 reduced holdings. 9 funds opened positions while 38 raised stakes. 49.13 million shares or 2.79% more from 47.80 million shares in 2017Q2 were reported. Sg Americas Ltd Liability has invested 0% in BioTime, Inc. (NYSEAMERICAN:BTX). Berson And Corrado Advisors Limited reported 0.12% stake. Parametric Portfolio Associate Ltd Company reported 12,839 shares. Connor Clark Lunn Inv Management invested in 108,650 shares. Riggs Asset Managment Inc invested in 13,100 shares or 0.02% of the stock. 1.28 million were accumulated by Artal Group Inc Sa. Tci Wealth Advsr accumulated 1,300 shares or 0% of the stock. Clarivest Asset Management Ltd Company holds 0% or 50,920 shares in its portfolio. Great West Life Assurance Can reported 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX). Vantage Advsrs Lc reported 500 shares. Wells Fargo & Mn owns 107,298 shares. State Street reported 1.36M shares. Quantitative Systematic Strategies Lc reported 18,000 shares stake. Geode Capital Mgmt Limited Liability holds 1.07M shares or 0% of its portfolio. Rhumbline Advisers has 75,801 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>